[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369598-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369598-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","polymerase-theta-expression-is-correlated-with-proliferative-capacity-but-not-with-dna-repair-deficiency-status-in-solid-tumors","Polymerase theta expression is correlated with proliferative capacity but not with DNA repair deficiency status in solid tumors","","Biomarker-driven analysis evaluates whether Polymerase theta (POLθ) expression and POLθ-associated mutational signatures can identify PARP-inhibitor–resistant solid tumors. Using TCGARNAseq expression and whole-exome/whole-genome sequencing data, the study compares HR-proficient versus HR-deficient cancers and relates POLθ to proliferation-linked transcriptional patterns and cell-cycle phase usage. Results show no significant POLθ expression difference by HR status, strong correlation with proliferation signatures, and linkage of POLθ-associated signatures to BRCA2-deficient cancers, with limited informativeness elsewhere. ",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/polymerase-theta-expression-is-correlated-with-proliferative-capacity-but-not-with-dna-repair-deficiency-status-in-solid-tumors/369598/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/polymerase-theta-expression-is-correlated-with-proliferative-capacity-but-not-with-dna-repair-deficiency-status-in-solid-tumors/369598.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What relationship did the study find between POLθ expression and HR status?","Question",{"text":63,"@type":64},"POLθ expression levels did not differ significantly between HR-proficient and HR-deficient cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"With what does POLθ expression correlate strongly?",{"text":68,"@type":64},"POLθ expression correlated strongly with proliferation-associated gene expression signatures and was predominantly observed in the S and G2/M phases of the cell cycle.",{"name":70,"@type":61,"acceptedAnswer":71},"Are POLθ-associated mutational signatures informative across all cancers?",{"text":72,"@type":64},"POLθ-associated mutational signatures correlated with POLθ expression levels only in BRCA2-deficient cancers; they are unlikely to be informative in other cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369598,1790919560,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","npj | precision oncology Brief communication  \n\n| Published in partnership with The Hormel Institute, University of Minnesota |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41698-025-01000-w](https://doi.org/10.1038/s41698-025-01000-w) |  |  |\n| Polymerase theta expression is correlated with proliferative capacity but not with DNA repair deﬁciency status in\u003Cbr>solid tumors\u003Cbr> Check for updates |  |  |\n| Zsoﬁa Sztupinszki1,2 , Regina Fiam3, Orsolya Pipek3, Miklos Diossy1,2, Judit Börcsök1, Aurel Prosz1, Istvan Csabai3 & Zoltan Szallasi1,2,4  |  |  |\n| Polymerase theta (POLθ) inhibitors were developed to overcome resistance to PARP inhibitor treatment in homologous recombination (HR) deﬁcient cancer. Biomarkers identifying PARP inhibitor-resistant cancer cases that speciﬁcally rely on POLθ activity for cancer cell survival will help to identify the sensitive patient population. From the TCGARNAseq data, we determined POLθ expression levels, and from whole-exomeand whole-genome sequencing data, we determined the number of POLθ-associated mutational signatures in solid tumors with various HR deﬁciencystatus. We found that POLθ expression levels did not differ signiﬁcantly between HR-proﬁcient and HR-deﬁcient cancers. However, POLθ expression correlated stronglywith proliferation-associated gene expression signaturesand was predominantly observed in theSand G2/M phases of the cell cycle. POLθ-associated mutational signatures are correlated with POLθ expression levels only in BRCA2-deﬁcient cancers. POLθ expression level and POLθ-associated mutational signatures may be indicative of POLθ inhibitor sensitivity in BRCA2-deﬁcient tumors, but are unlikely to be informative in other cancers. |  |  |\n| Cancer cells with deﬁcient functions of BRCA1 or BRCA2 often have an increased sensitivity to PARP inhibitors1. It is hypothesized that interfering either with the enzymatic function of PARP or with the release of PARP from DNA,(PARP trapping), augments DNA damages that are usually repaired by BRCA1 or BRCA2 action and in the absence of those functions the accumulation of DNA damages lead to cell death in the presence of PARP inhibitors. While the exact mechanism of action of PARP inhibitor activity in BRCA1/BRCA2 deﬁcient cancer is still debated2, it is evident that the complex interactions involving BRCA1/2 functions allow the activation of various backup mechanisms that overcome PARP inhibitor sensitivity, which are likely behind the often observed de novo or acquired resistance to this treatment.\u003Cbr>One such compensatory mechanism was identiﬁed by focusing on the essential role BRCA1/2 play in double-strand DNA break (DSB) repair. Leaving DSBs unrepaired is lethal, but HR deﬁcient cancer cells can rely on other DNA repair pathways, such as microhomology-mediated end-joining (MMEJ) or non-homologous end-joining (NHEJ) to repair DSBs and | survive. One of the central players in MMEJ is polymerase theta (POLθ), a DNApolymerasewithahelicase-like domainwith DNA-dependentATPase activity. POLθ plays an important role in the survival of HR deﬁcient cancer cells, and in some cases, depletion ofPOLθ in HR deﬁcient tumors may lead to enhanced cell death3,4. Considering the demonstrated synthetic lethality between POLθ and HR deﬁciency, it was proposed that inhibiting POLθ might bean efﬁcient therapeutic strategy to treat certain HR deﬁcient cancer cases either alone or in combination with PARP inhibitors5. Recently, industrial and academic labs have developed several small-molecule POLθ inhibitors6,7. The therapeutic efﬁcacy ofthese inhibitors will likely depend on whether the actual cancer relies on POLθ (as opposed to other DNA repair mechanisms) for survival in the absence of HR. There are also other biological functions whose inhibition may help to overcome PARP inhibitor resistance, such as the inhibition of USP1 or PARG8. Identifying which of these enzymes should be inhibited ina given cancer case for maximal clinical beneﬁt would r","cbCaibYZGSAmCcjW","https://ap.wps.com/l/cbCaibYZGSAmCcjW","pdf",947344,"English","# Results\n## Polymerase theta expression is not correlated with the level of immune cell infiltration in solid tumors","[{\"question\":\"What relationship did the study find between POLθ expression and HR status?\",\"answer\":\"POLθ expression levels did not differ significantly between HR-proficient and HR-deficient cancers.\"},{\"question\":\"With what does POLθ expression correlate strongly?\",\"answer\":\"POLθ expression correlated strongly with proliferation-associated gene expression signatures and was predominantly observed in the S and G2/M phases of the cell cycle.\"},{\"question\":\"Are POLθ-associated mutational signatures informative across all cancers?\",\"answer\":\"POLθ-associated mutational signatures correlated with POLθ expression levels only in BRCA2-deficient cancers; they are unlikely to be informative in other cancers.\"}]","Polymerase theta expression is correlated with proliferative capacity but not with DNA repair deficiency status in solid tumors | PDF",1790183613,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bad12d4000faa27de551b4043e320263.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73c109fb292553217d451bb15ca57b4c.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d8f00745925c83fe3c7b196343cee3d.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd90810e3bf7d959292e11116c496c9f.webp",980,1301]